Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat
- PMID: 3595539
- DOI: 10.1210/endo-121-2-704
Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat
Abstract
Oxyntomodulin (OXM), an intestinal glucagon-containing peptide extended at its C-terminal end by an octa-peptide, is one of the gut glucagon-like immunoreactants (GLI) or enteroglucagon. The distribution of OXM and glucagon was determined in the gastrointestinal tract and in the plasma of the rat. Reversed-phase HPLC, associated with RRA or RIA, performed with an N-terminally directed glucagon antiserum (GOL), was used. HPLC of intestinal extracts or plasma separated the GOL immunoreactivity into three peaks: two major peaks coeluting with a preparation of rat glicentin (peak I, partially purified from rat intestine) and porcine or rat OXM, respectively, and a smaller peak coeluting with glucagon. The behavior of the three peaks in the analytical systems matched that of glicentin, OXM, and glucagon, respectively, allowing their identification. The concentrations of OXM picomoles per g of tissue) gradually increased from the duodenum (9 +/- 1) to ileum (93 +/- 4), thereafter decreasing in cecum and colon (22 +/- 3). In the gut, OXM, glucagon, and peak I averaged 40%, 1%, and 59% of the total GLI, respectively. OXM was present in significant amounts in the pancreas (18% of GLI) and stomach (27% of GLI), two tissues in which it accounted, together with glucagon, for almost the totality of GLI. In 24 h-fasted rats, plasma concentrations of OXM, glucagon, and peak I, determined after HPLC with GOL antiserum, were 15.1 pM, 8.6 pM, and 12.3 pM, respectively. Two hours after refeeding, both OXM and peak I were significantly increased (P less than 0.05 and P less than 0.02) by a similar factor (2-fold), while glucagon remained unchanged. When the HPLC results were compared with RIA measurement of GLI (GOL antiserum) and glucagon (with a C-terminal glucagon antiserum) in plasma, enteroglucagon (GOL--C-terminal glucagon antiserum immunoreactivities) correlated well with the sum of OXM plus peak I. The combination of HPLC and RRA or RIA allows the unambiguous determination of OXM, glucagon, and glicentin (peak I) in tissues and plasma. In the rat intestine and in the plasma, OXM and glicentin appear roughly in the same ratio and seem to be the major components, if not the totality, of enteroglucagon.
Similar articles
-
Oxyntomodulin and glicentin: brain-gut peptides in the rat.Endocrinology. 1988 Dec;123(6):2782-7. doi: 10.1210/endo-123-6-2782. Endocrinology. 1988. PMID: 3197645
-
Development of an oxyntomodulin/glicentin C-terminal radioimmunoassay using a "thiol-maleoyl" coupling method for preparing the immunogen.Anal Biochem. 1988 Aug 15;173(1):151-9. doi: 10.1016/0003-2697(88)90172-8. Anal Biochem. 1988. PMID: 3189794
-
Molecular forms of glucagon-like immunoreactivity in porcine intestine and pancreas.Endocrinology. 1983 Mar;112(3):917-23. doi: 10.1210/endo-112-3-917. Endocrinology. 1983. PMID: 6822217
-
The biological significance of "enteroglucagon." Present status.Peptides. 1986;7 Suppl 1:37-42. doi: 10.1016/0196-9781(86)90161-0. Peptides. 1986. PMID: 3529053 Review.
-
The Enigmatic N-Terminal Domain of Proglucagon; A Historical Perspective.Front Endocrinol (Lausanne). 2021 Jun 11;12:683089. doi: 10.3389/fendo.2021.683089. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34177808 Free PMC article. Review.
Cited by
-
Plasma and tissue alterations of peptide YY and enteroglucagon in rats after colectomy.Yale J Biol Med. 1992 Jan-Feb;65(1):1-15. Yale J Biol Med. 1992. PMID: 1509780 Free PMC article.
-
From gut changes to type 2 diabetes remission after gastric bypass surgeries.Front Med. 2013 Jun;7(2):191-200. doi: 10.1007/s11684-013-0258-2. Epub 2013 Apr 4. Front Med. 2013. PMID: 23553469 Review.
-
Oxyntomodulin reduces hydromineral transport through rat small intestine.Dig Dis Sci. 1998 Aug;43(8):1814-23. doi: 10.1023/a:1018804307972. Dig Dis Sci. 1998. PMID: 9724174
-
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?Br J Pharmacol. 2009 Aug;157(8):1340-51. doi: 10.1111/j.1476-5381.2009.00376.x. Br J Pharmacol. 2009. PMID: 19681866 Free PMC article. Review.
-
Proglucagon-derived peptides: nomenclature, biosynthetic relationships and physiological roles.Diabetologia. 1988 Aug;31(8):563-6. doi: 10.1007/BF00264761. Diabetologia. 1988. PMID: 3065110 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources